UNSPSC 51334407: Fenimide

This classification denotes an antipsychotic agent with the molecular formula C13H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z48G09KOD, chemically known as 2,5-pyrrolidinedione, 4-ethyl-3-methyl-3-phenyl- but generally known as fenimide, which bears US NIH Compound Identifier 6068. European Medicines Agency schedules Fenimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07565MIG. The term FENIMIDE is an International Non-Proprietary Name.

UNSPSC 51334407 Fenimide is a Commodity code representing pharmaceutical products, but the recent opportunities posted under this code show minimal activity directly aligned with the code's nominal scope. State and local governments are instead sourcing naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs — none of which are fenimide-specific. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which serves Minnesota and Oregon). The work being solicited spans procurement of finished pharmaceutical products for community health initiatives, bulk generic drug supply agreements for government facilities, and exploratory market research on direct-to-manufacturer pharmacy programs.

Recent activity is concentrated in Florida, Texas, and Minnesota-Oregon. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, with a July 26, 2023 response date, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health facility; the contract includes a two-year initial term with optional one-year renewal and requires E-Verify compliance and workers' compensation insurance. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026, with a March 26, 2026 response deadline, establishes multi-contract vehicles for generic pharmaceuticals and OTC products distributed across state and local facilities through three authorized wholesalers; pricing is weighted 75 percent in evaluation and a 3 percent administrative fee applies to all purchases. The Texas HHS Commission RFI (HHS0017013), posted April 3, 2026, solicits vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, with no formal award or budget identified at this preliminary intelligence-gathering phase. The code shows limited recent fenimide-specific procurement activity; the tagged opportunities reflect broader pharmaceutical supply contracting that may include fenimide as one product line among many but do not foreground it as a primary procurement driver.